PGEN
Precigen IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.46B
P/E Ratio
—
EPS
$-1.37
Beta
1.12
52W High
$5.47
52W Low
$1.23
50-Day MA
$4.01
200-Day MA
$3.51
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
9.14
PEG Ratio
—
About Precigen Inc
Precigen, Inc. discovers and develops the next generation of cell and gene therapies in the United States. The company is headquartered in Germantown, Maryland.
Fundamentals
| Revenue (TTM) | $9.68M |
| Gross Profit (TTM) | $-36.47M |
| EBITDA | $-103.40M |
| Operating Margin | -474.60% |
| Return on Equity | -572.00% |
| Return on Assets | -44.30% |
| Revenue/Share (TTM) | $0.03 |
| Book Value | $0.06 |
| Price-to-Book | 66.69 |
| Price-to-Sales (TTM) | 150.58 |
| EV/Revenue | 144.04 |
| EV/EBITDA | -3.31 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 283.60% |
| Shares Outstanding | $353.93M |
| Float | $168.88M |
| % Insiders | 13.93% |
| % Institutions | 73.11% |
Analyst Ratings
Consensus ($9.50 target)
1
Strong Buy1
Buy1
HoldData last updated: 4/9/2026